CLINICAL AND DIAGNOSTIC VALUE OF THE CONTENT OF TISSUE NEUROTRANSMITTERS IN FUNCTIONAL AND INFLAMMATORY BOWEL DISEASES

DOI: https://doi.org/None

I.V. Kozlova, Yu.N. Myalina, O.E. Badieva Saratov State Medical University named after V.I. Razumovsky, B. Kazachya Str., 112, Saratov, Russian Federation, 410012

Introduction. There is observed an incidence rate of irritable bowel syndrome (IBS) and inflammatory bowel diseases (IBD). The aim of the study. The study of the quantitative density of mast cells of the colon; enterochromaffin cells secreting serotonin, melatonin, vasointestinal peptide (VIP) in comparison with the morphological, functional changes in diseases of the colon. Methods. There were examined 255 patients with IBS and IBD. Patients were observed dynamically at different stages of the disease. There were applied clinical, endoscopic, morphological, immunohistochemical methods. Results. It is shown that For non-specific colitidess (chronic ulcerative and non-ulcer) are typical of similar functional changes in tissue density quantification of neurotransmitters in the form of increasing the number of Colonocyte producing melatonin, serotonin, were shown to be typical on the background of oppression of activity of apudocytes producing VIP and mast cells. For Crohn's disease there was typical hyperplasia of the endocrine cells, a significant increase in the number and functional hyperplasia of apudocytes producing melatonin on the background of a decrease of the number of cells producing serotonin. Conclusion. Thus, the quantitative and qualitative features of the characteristics of such components as the total population of apudocytes, ratio apudocytes producing melatonin and serotonin, functional morphology of VIP-producing cells Crohn's disease can be categorized as apudopaty.
Keywords: 
Crohn's disease, ulcerative colitis, IBS, VIP
Список литературы: 
  1. Rivkin V.L., Kapuller L.L., Belousova E.A. Koloproktologiya: rukovodstvo dlya vrachey. M.: GE`OTAR-Media, 2011. [Rivkin V.L., Kapuller L.L., Belousova E.A. Koloproktologija: ruk-vo dlja vrachej. M.: GJeOTAR-Media, 2011 (in Russian)]
  2. Peery A.F., Dellon E.S., Lund J. et al. Burden of gastrointestinal disease in the United States: 2012 update, Gastroenterology. 2012; 143: 1179–87 e3.
  3. Zhao Y., Zou D., Wang R. et al. Dyspepsia and irritable bowel syndrome in China: a population-based endoscopy study of prevalence and impact, Aliment Pharmacol Ther. 2010; 32: 562–72.
  4. Ford A.C., Marwaha A., Lim A., Moayyedi P. Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia, Clin Gastroenterol Hepatol. 2010; 8: 401–9.
  5. Cosnes J., Gower-Rousseau C., Seksik P., Cortot A. Epidemiology and natural history of inflammatory bowel diseases, Gastroenterology. 2011; 140: 1785–94.
  6. Van Assche G., Dignass A., Panes J. et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. J. Crohn’s Colitis. 2010; 4: 7–27.
  7. Lichtenstein G.R., Hanauer S.B., Sandborn W.J. Management of Crohn’s disease in adults. Am. J. Gastroenterol. 2009; 104: 465–83.
  8. Burulova O.E., Kozlova I.V., Myalina Yu.N. Sindrom razdrazhennogo kishechnika kak biopsihosocial`noe zabolevanie (obzor). Saratovskiy nauchno-medicinskiy zhurnal. 2012; 8 (2): 232–7. [Burulova O.E., Kozlova I.V., Mjalina Ju.N. Sindrom razdrazhennogo kishechnika kak biopsihosocial’noe zabolevanie (obzor). Saratovskij nauchno-medicinskij zhurnal. 2012; 8 (2): 232–7 (in Russian)]
  9. Frol`kis A.V. Funkcional`nye zabolevaniya zheludochno-kishechnogo trakta. L.: Medicina, 1991. [Frol’kis A.V. Funkcional’nye zabolevanija zheludochno-kishechnogo trakta. L.: Medicina, 1991 (in Russian)]
  10. Pal`cev M.A., Kvetnoy I.M. Rukovodstvo po neyroimmunoe`ndokrinologii 2-e izd. M.: Izdatel`stvo «Medicina», 2008. [Pal’cev M.A., Kvetnoj I.M. Rukovodstvo po nejroimmunojendokrinologii 2-e izd. M.: Izdatel’stvo «Medicina», 2008 (in Russian)]
  11. Engel M.A., Becker C., Reeh P.W., Neurath M.F. Role of sensory neuronsin colitis: increasing evidence for a neuroimmune link in the gut, Inflamm Bowel Dis. 2011; 17 (4): 1030–3.
  12. Chichlowski M., Westwood G.S., Abraham S.N., Hale L.P. Role of mast cells in inflammatory bowel disease and inflammation-associated colorectal neoplasia in IL-10-deficient mice, PLoS ONE. 2010; 5: e12220.
  13. Philpott H., Gibson P., Thien F. Irritable bowel syndrome – An inflammatory disease involving mast cells, Asia Pac Allergy. 2011; 1 (1): 36–42.
  14. Da Mota D.L., Yamada J., Gerge L.L., Pinheiro P.B. An immunohistochemical study on the pancreatic endocrine cells of the three-toed sloth, Bradypus variegates. Arch. Histol. Cytol. 1992; 55: 203–9.
  15. Abad C. et al. VIP in Inflammatory Bowel Disease: State of the Art, Endocr Metab Immune Disord Drug Targets. 2012; 12 (4): 316–22.
  16. Vorob`ev G.I., Halif I.L. Nespecificheskie vospalitel`nye zabolevaniya kishechnika. M.: Miklosh, 2008. [Vorob’ev G.I., Halif I.L. Nespecificheskie vospalitel’nye zabolevanija kishechnika. M.: Miklosh, 2008 (in Russian)]
  17. Mozaffari S., Abdollahi M. Melatonin, a promising supplement in inflammatory bowel disease: a comprehensive review of evidences. Curr Pharm Des. 2011; 7: 4372–8.